Analysis of the Incidence and Risk Factors of Precocious Puberty in Girls during the COVID-19 Pandemic

Table 2

Hormone levels in the study population.

Variable	Control	CPP	PT	P
Population number	124	58	58
Serotonin (ng/mg)	11.55 ± 4.33	9.99 ± 5.48	8.73 ± 4.05	<0.001
Melatonin (pg/mg)	0.17 ± 0.06	0.19 ± 0.09	0.21 ± 0.10	0.002
Leptin (ng/mg)	0.21 ± 0.07	0.36 ± 0.07	0.28 ± 0.08	<0.001
Kisspeptin (pg/mg)	309.55 ± 85.30	354.17 ± 129.34	352.87 ± 105.66	0.005
LH (mIU/mL)	0.11 ± 0.04	1.96 ± 2.50	0.15 ± 0.09	<0.001
FSH (mIU/mL)	1.77 ± 0.74	3.48 ± 1.91	2.49 ± 1.45	<0.001
E2 (pg/mL)	11.72 ± 9.44	30.12 ± 18.71	19.00 ± 15.38	<0.001
Vitamin D (ng/mL)	27.61 ± 8.64	13.76 ± 4.10	15.26 ± 6.11	<0.001

CPP, central precocious puberty; PT, premature thelarche; LH, luteinizing hormone; FSH, follicle stimulation hormone; E2, estrogen.